ANTICOV Trial Finds Nitazoxanide/Ciclesonide Drug Combination Does Not Reduce Hospitalisation Risk in Patients With Mild COVID-19
, News, ANTICOV, NCT04920838, Feb 2022
RCT with 591 nitazoxanide/ciclesonide and 557 control patients, up to 7 days from onset, showing higher progression, without statistical significance. Control patients were assigned to paracetamol as needed for fever or pain, however treatment patients were also allowed to take paracetamol as needed for fever or pain.
|
risk of progression, 104.3% higher, RR 2.04, p = 0.09, treatment 16 of 591 (2.7%), control 7 of 557 (1.3%), adjusted per study, odds ratio converted to relative risk, SpO2 ≤93 or death, day 21, Table 13.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
ANTICOV et al., 28 Feb 2022, Randomized Controlled Trial, multiple countries, preprint, 1 author, this trial compares with another treatment - results may be better when compared to placebo, this trial uses multiple treatments in the treatment arm (combined with ciclesonide) - results of individual treatments may vary, trial NCT04920838 (history) (ANTICOV).